7-Hydroxyquinolinone CAS 70500-72-0 Puritas > 98.0% (HPLC)
Ruifu Chemical Supple Brexpiprazole Intermedia
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl) piperazinum Hydrochloridum CAS 913614-18-3
7-(4-Chlorobutoxy) quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3
Nomen chemicum | 7-Hydroxyquinolinone |
Synonyma | 2,7-Dihydroxyquinoline;7-Hydroxy-1,2-Dihydroquinolin-2-unum;7-Hydroxyquinolin-2(1H)-one;3,4-Dihydro-7-Hydroxycarbostylil;7-Hydroxycarbostyril |
CAS Number | 70500-72-0 |
CATTUS Number | RF-PI1979 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C9H7NO2 |
M. Pondus | 161.16 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad Yellow Firmus |
Puritas / Analysis Methodus | >98.0% (HPLC) |
Infrared Imaginis | Conformat ut Structure |
Proton NMR Spectrum | Conformat ut Structure |
Damnum in Siccatio | <1.00% |
Metalla gravis | <0.002% |
Totalis immunditias | <2.0% |
Fasciae vita | Annis II |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Brexpiprazole (CAS: 913611-97-9) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
7-Hydroxyquinolinone (CAS: 70500-72-0) substituitur carbostyrilis derivativis pharmaceuticae intermedii.7-Hydroxyquinolinone media est Brexpiprazolis (CAS: 913611-97-9).Brexpiprazole medicamentum est candidatus utilis in curatione et praecavatione perturbationum mentalium inclusorum CN perturbationes.Brexpiprazole est genus atypicum antipsychoticum.Est dopamine D2 receptor partialis agonist.Cum nova actio modulatoris serotonin-dopamine, Brexpiprazole adhiberi potest ad schizophreniae tractationem et ad adiunctivam curationem pro tristitia.Brexpiprazole etiam efficaciam et tolerabilitatem in curationibus adiunctivis statutis inordinationis depressivae (MDD).Recentes studium etiam Brexpiprazole suggessit posse meliorare PCP defectus cognitivas in muribus per receptores 5-HT1A inductos.